METiS Technologies Selected for Two 2024 Venture50 Lists, Highlighting Leadership in AI + Drug Delivery_News_剂泰科技（北京）股份有限公司

CN

Home

About us

Platforms

Pipeline

Partners

News

Investors

Careers

Contact us
Home News News
METiS Technologies Selected for Two 2024 Venture50 Lists, Highlighting Leadership in AI + Drug Delivery
2025.01.09

On January 9, 2025, the results of the 2024 VENTURE50 selection, initiated by Zero2IPO Group (1945.HK) and ChinaVenture, were officially announced. As a global leader in AI + drug delivery, METiS Technologies was selected for both the “2024 VENTURE50 Elite” list and the 2024 ChinaVenture Healthcare VENTURE50 list, underscoring the company’s innovation and growth in the biopharmaceutical sector.

METiS Technologies Selected for Two 2024 Venture50 Lists, Highlighting Leadership in AI + Drug Delivery(图1)

METiS Technologies Selected for Two 2024 Venture50 Lists, Highlighting Leadership in AI + Drug Delivery(图1)

Recommended News
METiS Selected as MIT Technology Review's 50 Smartest Companies (TR50)
METiS Selected as MIT Technology Review's 50 Smartest Companies (TR50)
2025.09.13
News
METiS Technologies Closes RMB 400 Million Series D Financing to Power Beijing’s Biopharmaceutical Innovation Engine
METiS Technologies Closes RMB 400 Million Series D Financing to Power Beijing’s Biopharmaceutical Innovation Engine
2025.08.01
News
METiS Technologies Showcases AI-Powered Nanodelivery Platform at the 2025 Controlled Release Society Annual Meeting
METiS Technologies Showcases AI-Powered Nanodelivery Platform at the 2025 Controlled Release Society Annual Meeting
2025.07.22
News
METiS Pharmaceuticals Announces Formation of Scientific Advisory Board Comprising World-Renowned Experts
METiS Pharmaceuticals Announces Formation of Scientific Advisory Board Comprising World-Renowned Experts
2025.04.25
News
This website uses cookies.
This website uses cookies to improve your experience when visiting this website. However, if you do not agree, you can also choose to cancel.
For more information, please refer to our Privacy Policy.